Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: A randomized controlled trial

Cho, Sung‐Joon; Yook, Keunyoung; Kim, Borah; Choi, Tai Kiu; Lee, Kang Soo; Kim, Young Kook; Lee, Ji Eun; Suh, Shin Young; Yook, Ki Hwan; Lee, Sanghyuk

doi:10.1016/j.pnpbp.2010.11.006

Cited by 50 publications

(32 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[20] A single small study using mirtazapine demonstrated small benefit for mirtazapine on negative symptoms, but subjects gained more than 5 kg compared to those on placebo. [21]…”

Section: Targeting Nonpsychotic Symptomsmentioning

confidence: 99%

Polypharmacy for schizophrenia

Ballon

Stroup

2013

Current Opinion in Psychiatry

View full text Add to dashboard Cite

Purpose of review Combining psychotropic medications is common for people diagnosed with schizophrenia facing a variety of clinical circumstances. This review provides an update on evidence regarding the effectiveness of polypharmacy approaches. Recent findings Epidemiology studies have demonstrated that polypharmacy is extremely common but evidence regarding all polypharmacy approaches for schizophrenia from randomized controlled trials remains scarce. Combinations of antipsychotic medicines are unsupported by evidence. Antidepressants are commonly used to treat depressive symptoms; this logical role for antidepressants has little support from RCTs but may be associated with lower suicide and all-cause mortality. No evidence supports the use of benzodiazepines for schizophrenia; possible risks of benzodiazepines including increased mortality rates revealed in observational studies warrant caution and further study. Summary The lack of evidence regarding common treatment strategies exacerbates the tremendous challenge of providing optimal pharmacotherapy for individuals with schizophrenia. Comparative effectiveness research, using observational methods when appropriate and randomized controlled trials when possible, is needed to inform clinical practice, use resources wisely, and improve outcomes.

show abstract

“…[20] A single small study using mirtazapine demonstrated small benefit for mirtazapine on negative symptoms, but subjects gained more than 5 kg compared to those on placebo. [21]…”

Section: Targeting Nonpsychotic Symptomsmentioning

confidence: 99%

Polypharmacy for schizophrenia

Ballon

Stroup

2013

Current Opinion in Psychiatry

View full text Add to dashboard Cite

show abstract

“…All of these receptors seem to be involved in the modulation of neurocognition (Akhondzadeh et al, 2009;Galletly, 2009;Sumiyoshi et al, 2007). A proneurocognitive effect of adjunctive mirtazapine was first reported in an open label study by Delle Chiae et al (2007), which has subsequently been replicated in smaller randomized controlled trials (RCT) Cho et al, 2011).…”

Section: Introductionmentioning

confidence: 99%

Predictors and mediators of add-on mirtazapine-induced cognitive enhancement in schizophrenia – A path model investigation

et al. 2013

View full text Add to dashboard Cite

“…The latter study was extended for a further 6 weeks and patients, who had already received mirtazapine, showed further improvements in some cognitive functions as shown by the scores in the Stroop Dots time and Trail Making Test part B [26]. Finally, an 8-week double-blind clinical trial with 21 stabilized schizophrenia patients demonstrated the efficacy of adjunctive mirtazapine to risperidone with regard to cognitive symptoms [27].…”

Section: Mirtazapinementioning

confidence: 96%